ArticleScientific reports2025
A comprehensive descriptive, predictive, and prescriptive analysis of antibiotic products' demand pre-, amid, and post-COVID-19 in Iran.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Supply Chain Vulnerabilities in First-Line Treatments for Sexually Transmitted Infections: Implications for U.S. Public Health Preparedness.medRxiv : the preprint server for health sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 has affected healthcare businesses such as medicine and face mask distribution networks, particularly the antibiotics distribution sector, because antibiotics significantly combat infections during COVID-19. Hence, re-coordinating the antibiotics supply chain according to changes in antibiotic consumption rates is crucial post-COVID-19 to avoid shortages and the perishing of antibiotics. This paper proposes a data analytical approach to investigate the antibiotics demand fluctuations before, during, and after COVID-19 using several descriptive, predictive, and prescriptive analyses, including a graphical trend study, descriptive statistics, two-sample mean hypothesis test, Analysis of Variance (ANOVA), time series machine learning forecasters, and Pareto analysis. The proposed data analytical approach is employed to analyze the consumption rate of the 73 popular antibiotic products belonging to the top-11 list of antibiotics in Iran, including Amoxicillin, Co-amoxiclav, Azithromycin, Cefalexin, Cefixime, Ciprofloxacin, Clindamycin, Doxycycline, Levofloxacin, Metronidazole, and Penicillin. The consumption volume and Doses used by 1000 Inhabitants per Day (DID) are collected for ten years, from 2013 to 2023, in a data set of size 3582. The results showed the considerable impacts of COVID-19 on the consumption trend of Amoxicillin and Azithromycin, a decline in Penicillin parental consumption in 2021 due to COVID-19 vaccination, and a higher share of parental Levofloxacin during COVID-19. In addition, several prescriptive analyses are proposed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.